212 related articles for article (PubMed ID: 34249747)
1. HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis.
Egebjerg K; Harwood CD; Woller NC; Kristensen CA; Mau-Sørensen M
Front Oncol; 2021; 11():693394. PubMed ID: 34249747
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of HER2/neu expression in different types of salivary gland tumors: a systematic review and meta-analysis.
Javaheripour A; Saatloo MV; Vahed N; Gavgani LF; Kouhsoltani M
J Med Life; 2022 May; 15(5):595-600. PubMed ID: 35815077
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
4. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.
Williams CYK; Townson AT; Terry N; Schmitt NC; Sharma A
Laryngoscope; 2023 Mar; 133(3):476-484. PubMed ID: 35567387
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis.
Egebjerg K; Garbyal RS; Hasselby JP; Baeksgaard L; Mau-Sørensen M
Crit Rev Oncol Hematol; 2021 May; 161():103339. PubMed ID: 33865993
[TBL] [Abstract][Full Text] [Related]
6. SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma.
Hsieh MS; Lee YH; Chang YL
Hum Pathol; 2016 Oct; 56():134-42. PubMed ID: 27327192
[TBL] [Abstract][Full Text] [Related]
7. The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma.
Prasad AR; Savera AT; Gown AM; Zarbo RJ
Arch Pathol Lab Med; 1999 Sep; 123(9):801-6. PubMed ID: 10458827
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of epidermal growth factor receptor in various pathological types of salivary gland cancers.
Fujiwara H; Kodama Y; Shimoda H; Teshima M; Shinomiya H; Nibu KI
Auris Nasus Larynx; 2024 Jun; 51(4):755-760. PubMed ID: 38852332
[TBL] [Abstract][Full Text] [Related]
9. Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma.
Nishijima T; Yamamoto H; Nakano T; Nakashima T; Taguchi K; Masuda M; Motoshita J; Komune S; Oda Y
Hum Pathol; 2015 Nov; 46(11):1730-43. PubMed ID: 26345124
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Witte HM; Gebauer N; Lappöhn D; Umathum VG; Riecke A; Arndt A; Steinestel K
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260165
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
Maruya S; Shirasaki T; Nagaki T; Kakehata S; Kurotaki H; Mizukami H; Shinkawa H
BMC Cancer; 2009 Feb; 9():72. PubMed ID: 19250538
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.
Guazzo E; Cooper C; Wilkinson L; Feng S; King B; Simpson F; Porceddu S; Panizza B; Coward JIG
Head Neck; 2021 Mar; 43(3):768-777. PubMed ID: 33169486
[TBL] [Abstract][Full Text] [Related]
13. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.
Ross JS; Gay LM; Wang K; Vergilio JA; Suh J; Ramkissoon S; Somerset H; Johnson JM; Russell J; Ali S; Schrock AB; Fabrizio D; Frampton G; Miller V; Stephens PJ; Elvin JA; Bowles DW
Ann Oncol; 2017 Oct; 28(10):2539-2546. PubMed ID: 28961851
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of PLAG1 immunohistochemical determination in salivary gland tumors.
Rotellini M; Palomba A; Baroni G; Franchi A
Appl Immunohistochem Mol Morphol; 2014; 22(5):390-4. PubMed ID: 23958548
[TBL] [Abstract][Full Text] [Related]
16. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
Suzuki S; Dobashi Y; Minato H; Tajiri R; Yoshizaki T; Ooi A
Virchows Arch; 2012 Sep; 461(3):271-82. PubMed ID: 22828828
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers.
Khurram SA; Speight PM
Head Neck Pathol; 2019 Jun; 13(2):140-148. PubMed ID: 29671211
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours.
Andreadis D; Epivatianos A; Mireas G; Nomikos A; Poulopoulos A; Yiotakis J; Barbatis C
J Laryngol Otol; 2006 Apr; 120(4):298-304. PubMed ID: 16623973
[TBL] [Abstract][Full Text] [Related]
19. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
Foschini MP; Krausz T
Semin Diagn Pathol; 2010 Feb; 27(1):77-90. PubMed ID: 20306833
[TBL] [Abstract][Full Text] [Related]
20. Maspin and MCM2 immunoprofiling in salivary gland carcinomas.
Ghazy SE; Helmy IM; Baghdadi HM
Diagn Pathol; 2011 Sep; 6():89. PubMed ID: 21943228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
